Erik Wiklund

Erik Wiklund

Company: Targovax ASA

Job title: Chief Executive Officer

Email: erik.wiklund@targovax.com

Seminars:

Panel Discussion – Evaluating Combination Therapies to Maximise Anti-Tumour Immune Activity 4:00 pm

• What is the ideal combination strategy for neoantigen vaccines? • What are the best combination therapies that maximise T cell responses and efficacy? • How to identify a clear biologic effect caused by combination • Improving clinical efficacy through immunotherapy combinationsRead more

day: Day Two

Clinical Combination Strategies with Oncolytic Vaccines in Solid Tumours 3:30 pm

• Harnessing the clinical activity of oncolytic adenoviral vector ONCOS-102 in solid tumours of different origin • Identifying strong and consistent patterns of immuno-modulation with both PD1 blockade and chemotherapy • Utilising the selection of future combination strategies based on tumour biopsy translational dataRead more

day: Day Two

© Copyright 2022 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.